Sign in

CIK 0001662774

  • Non-accelerated filer
  • Smaller reporting company

IRulya Therapeutics Inc.

Sign in to watch
Ticker
IRLA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
901024039
Phone
+1 203-208-8994
Business address
101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
Former names
Quince Therapeutics, Inc., Cortexyme, Inc.
  1. 4/A Grant or award Chief Business Officer acquired 113,569 shares (grant or award)
  2. 4 Grant or award Chief Executive Officer acquired 64,589 shares (grant or award)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Grant or award Chief Medical Officer acquired 24,336 shares (grant or award)
  5. 3 Insider Initial Statement of Ownership
  6. 4 Grant or award Director acquired 519,283 shares (grant or award)
  7. 3 Insider Initial Statement of Ownership
  8. 4 Grant or award Director acquired 200,002 shares (grant or award)
  9. 4 Grant or award Chief Business Officer acquired 16,224 shares (grant or award)
  10. 3 Insider Initial Statement of Ownership
  11. 4 Derivatives Options or other derivatives
  12. 3 Insider Initial Statement of Ownership
  13. 4 Grant or award Chief Accounting Officer & VP acquired 34,000 shares (grant or award)
  14. 4 Grant or award Chief Legal & Adm. Officer acquired 140,000 shares (grant or award)
  15. 4 Grant or award Interim CEO, COO & CFO acquired 175,000 shares (grant or award)
  16. 4 Grant or award EVP, Preclinical Development acquired 155,500 shares (grant or award)
  17. 4 Grant or award Chief Medical Officer acquired 140,000 shares (grant or award)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 6 of 11 · 211 filings